Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Ma, Chao ^a   Kuang, Anren ^b   Xie, Jiawei ^c  

^a QINGDAO UNIVERSITY   (China)

^b FIRST AFFILIATED HOSPITAL   (China)

^c Affiliated Hospital   (China)

Author keywords

Humans; Iodine radioisotopes *therapeutic use ; Thyroglobulin *blood ; Thyroid neoplasms blood; *radiotherapy ; Tumor markers, biological *blood

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN;

ADVERSE OUTCOME; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; DRUG EFFECT; FOLLOW UP; HUMAN; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; THYROID CARCINOMA; TREATMENT OUTCOME; TUMOR VOLUME; WHOLE BODY SCINTISCANNING;

EID: 70249121971     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006988.pub2     Document Type: Review

References (50)

1. * Koh JM, Kim ES, Ryu JS, et al. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study. Clinical Endocrinology 2003;58:421-427
2. * Pacini L, Agate R, Elisei M. Outcome of differentiated thyroid cancer with detectable serum Thyroglobulin and negative 131I whole body scan: comparison of patients treated with high 131I activities versus untreated patients. The Journal of Clinical Endocrinology and Metabolism 2001;86:4092-4097
3. * Tian R, Pan M, Kuang A. Evaluation of I-131 therapy for differentiated thyroid carcinoma patients with elevated thyroglobulin and negative I-131whole body scan. Chinese Journal of Nuclear Medicine 2003;23:27-28
4. Alexander C, Bader JB, Schaefer A, et al. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998;39:1551-1554 (Pubitemid 28459885)
5. Black EG, Sheppard MC. Serum thyroglobulin measurements in thyroid cancer: evaluation of false positive results. Clin Endocrinol (Oxford) 1991;35:519.
6. Brendel AJ, Lambert B, Guyot M, et al. Low levels of serum thyroglobulin after withdrawl of thyroid suppression therapy in the follow-up of differentiated thyroid carcinoma. European Journal of Nuclear Medicine 1990;16:35-38 (Pubitemid 20085684)
7. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger MJ. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?. Clin Endocrinol Metab 2000;85:175-178 (Pubitemid 32268810)
8. Chao Ma, Anren Kuang, Jiawei Xie, et al. The Possible Explanations for Patients with Discordant Findings of Serum Thyroglobulin and 131I Whole-body Scan. J Nucl Med 2005;46:1473-1480
9. Chao Ma, Jiawei Xie, Anren Kuang. Is Blind 131I Therapy Justified for Patients with Negative Tg and Positive 131IW. J Nucl Med 2005; 46:1164-1170
10. Clark PM, Beckett G. Can we measure serumthyroglobulin? Annals of clinical biochemistry. Annals of clinical biochemistry 2002;39:196-202.
11. Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37-46.
12. De Keizer B, Koppeschaar HP, Zelissen PM, et al. Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin.. Europe Journal of Nuclear Medicine 2001;28:198-202. (Pubitemid 32186635)
13. de Vathaire F, Schlumberger M, Delisle MJ. Leukaemias and cancers following iodine-131 administration for thyroid cancer.. Br J Cancer 1997;75:734-739 (Pubitemid 27091090)
14. DeGroot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment, and course of papillary thyroid carcinoma.. J Clin Endocrinol Metab 1990;71:414. (Pubitemid 20261828)
15. Fatourech V, Hay ID, Javedan H, Wiseman G.A. Mullan B P, Gorman C A. Lack of impact of radioiodine therapy in Thyroglobulinpositive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. The Journal of Clinical Endocrinology and Metabolism 2002;87:1521-1526 (Pubitemid 34615232)
16. Fatourechi V, Hay ID. Treating the patients with differentiated thyroid cancer with thyroglobulin-positive surveillance. Seminars in Nuclear Medicine 2000;25:443-446
17. Higgins JPT, Thompson SG. Quantifying heterogeneity in a metaanalysis. Statistics in medicine 2002;21:1539-1558
18. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library Chichester, UK: John Wiley & Sons, Ltd 2005, issue 3.
19. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
20. Holzer S, Reiners C, Mann K, Bamberg M, Rothmund M, Dudeck J, Stewart AK, Hundahl SA. Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. US and German Thyroid Cancer Group. Cancer 2000; 89:192-201. (Pubitemid 30451291)
21. Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK, Holzer S. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996, US and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000;89:202-217
22. Hyer S, Vini L, O'Connell M, et al. Testicular dose and fertility in men following 131therapy for thyroid cancer. Clinical Endocrinology 2002;56:755-758 (Pubitemid 34785906)
23. Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. Journal of Nuclear Medicine 1994;35:257-262
24. Mackenzie EJ, Mortimer RH. Thyroid nodules and thyroid cancer. The Medical Journal of Australia 2004;180:242-247
25. Maxon HR, Thomas SR, Boehringer A, et al. Low iodine diet in 1131 ablation of thyroid remnants. Clinical Nuclear Medicine 1983; 8:123-126 (Pubitemid 13132215)
26. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. The Journal of Clinical Endocrinology and Metabolism 2001;86:1447-1463 (Pubitemid 32374886)
27. Mazzaferri EL, Robbins RJ, Spence CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.. J Clin Endocrinol Metab 2003;88:1433-1441 (Pubitemid 36623351)
28. McDougall IR. 131I treatment of 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated?. Thyroid 1997;7:669-672
29. Mertens IJ, De Klerk JM, Zelissen PM, et al. Undetectable serum thyroglobulin in a patient with metastatic follicular thyroid cancer. Clinical Nuclear Medicine 1999;24:346-349
30. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses.. Lancet 1999;354:1896-1900
31. Muller-Gartner HW, Schneider C. Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. Cancer 1988;61:976-981 (Pubitemid 18058611)
32. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. The Journal of Clinical Endocrinology and Metabolism 1994;79:98-105. (Pubitemid 24221167)
33. Pacini F, Lippi F, Formica N, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. Journal of Nuclear Medicine 1987;28:1888-1891 (Pubitemid 18017100)
34. Pacini F, Pinchera A. Serum and tissue thyroglobulin measurement: clinical applications in thyroid disease. Biochimie 1999;81:463-467
35. Pineda JD, Lee T, Robbins J. Treating metastatic thyroid cancer. Endocrinologist 1993;3:433-442
36. Pineda JD, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. The Journal of Clinical Endocrinology and Metabolism1995;80:1488-1492
37. Rudavsky AZ, Freeman LM. Treatment of scan-negative, thyroglobulin- positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone. J Clin Endocrinol Metab 1997;82:11.
38. Samaan NA, Schultz PN, Haynie TP, Ordonez NG. Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. The Journal of clinical endocrinology and metabolism 1985;60:376-380 (Pubitemid 15129587)
39. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest x-ray.. Journal of Nuclear Medicine 1988;29:1790-1794 (Pubitemid 18264912)
40. Schlumberger M, Mancusi F, Baudin E, et al.131-I therapy for elevated thyroglobulin levels. Thyroid 1997;7:273-276 (Pubitemid 27190595)
41. Schlumberger MJ. Papillary and follicular thyroid carcinoma. The New England Journal of Medicine 1998;338:297-306.
42. Schlumberger MJ. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 1999;22(suppl 11):3-7.
43. Sherman SI, Tielens ET, Sostre S, et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. The Journal of clinical endocrinology and metabolism1994; 78:629-634
44. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry. Cancer 1998;83:1012-1021
45. Spencer CA, Takeuchi M, Kazarosyan M. Current Status and Performance Goals for Serum Thyroglobulin Assays. Clinical Chemistry 1996;42:164-173.
46. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases. In: Egger M, Davey Smith G, Altman DG, editors(s). Systematic Reviews in Health Care; Meta-analysis in Context., London: BMJ Publishing Group 2001:189-208.
47. Stojadinovic A, Ghossein RA, Hoos A, Ronald A, Marshall J, Ronald H, et al. Hurtle cell carcinoma: A critical histopathologic appraisal. Journal of Clinical Oncology 2001;19:2616-2625 (Pubitemid 32441366)
48. Tenenbaum F, Corone C, Schlumberger M, Parmentier C. Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease [abstract]. Eur J Cancer 1996;32A: 1262. (Pubitemid 126783095)
49. van den Bergh JP, Pieters GF, Beex LV, et al. Compared to whole body scanning thyroglobulin assay is reliable in the follow-up of thyroidectomized patients with thyroid carcinoma. Ned Tijdschr Geneeskd 1993;137:1344-1348.
50. Van Tol KM, Jager PL, De Vries EG, et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Europe Journal of Endocrinololy 2003;148:589-596